<DOC>
	<DOCNO>NCT00370669</DOCNO>
	<brief_summary>compare effect intravitreal bevacizumab alone combination triamcinolone acetonide laser photocoagulation clinically significant macular edema ( CSME )</brief_summary>
	<brief_title>Effect Intravitreal Bevacizumab Clinically Significant Macular Edema</brief_title>
	<detailed_description>enter 150 eye study recruitment case finish recently.Eligible eye randomly assign one study arm include intravitreal bevacizumzb , intravitreal bevacizumzb/triamcinolone macular photocoagulation group . Every patient need least 1 year followup . During time BCVA , OCT , FA do patient inaccording interpretation data fundus exam repeatation injection do .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>case clear medium IOP 23 mm/Hg female menopause least 12 month 2 contraceptive root visual acuity 20/50 20/320 PRP N.d YAG laser past 6 month intraocular surgery past 12 month CVA past 12 month blood sugar 250 active infection extraocular adnexa</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Bevacizumab</keyword>
	<keyword>CSME</keyword>
	<keyword>MPC</keyword>
	<keyword>Triamcinolone acetonide</keyword>
</DOC>